Ephraim Fuchs

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi request reprint Hematopoietic stem cell transplant as a platform for tumor immunotherapy
    Ephraim J Fuchs
    Division of Immunology and Hematopoiesis, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Curr Opin Mol Ther 6:48-53. 2004
  2. pmc Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide
    Ashley Munchel
    Divisions of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Pediatr Rep 3:e15. 2011
  3. doi request reprint Human leukocyte antigen-haploidentical stem cell transplantation using T-cell-replete bone marrow grafts
    Ephraim J Fuchs
    Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21287, USA
    Curr Opin Hematol 19:440-7. 2012
  4. pmc Haploidentical transplantation for hematologic malignancies: where do we stand?
    Ephraim J Fuchs
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA
    Hematology Am Soc Hematol Educ Program 2012:230-6. 2012
  5. ncbi request reprint Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation
    Leo Luznik
    Divisions of Hematologic Malignancies and Immunology Hematopoiesis, Johns Hopkins Oncology Center, Baltimore, MD 21231, USA
    Cancer Control 9:123-37. 2002
  6. pmc HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide
    Leo Luznik
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Biol Blood Marrow Transplant 14:641-50. 2008
  7. pmc Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes
    Erica D Warlick
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, United States
    Leuk Res 32:1439-47. 2008
  8. pmc High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation
    Leo Luznik
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 288 Bunting Blaustein Cancer Research Building, Baltimore, MD 21231, USA
    Immunol Res 47:65-77. 2010
  9. pmc The allogeneic effect revisited: exogenous help for endogenous, tumor-specific T cells
    Heather J Symons
    Division of Cancer Immunology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Biol Blood Marrow Transplant 14:499-509. 2008
  10. pmc High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomas
    Douglas E Gladstone
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21287, USA
    Leuk Lymphoma 52:2076-81. 2011

Collaborators

Detail Information

Publications33

  1. ncbi request reprint Hematopoietic stem cell transplant as a platform for tumor immunotherapy
    Ephraim J Fuchs
    Division of Immunology and Hematopoiesis, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Curr Opin Mol Ther 6:48-53. 2004
    ....
  2. pmc Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide
    Ashley Munchel
    Divisions of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Pediatr Rep 3:e15. 2011
    ..These outcomes suggest that mini-haploBMT with post-transplantation Cy is associated with acceptably low toxicities and can provide longterm survival, if not cure, for many patients with advanced hematologic malignancies...
  3. doi request reprint Human leukocyte antigen-haploidentical stem cell transplantation using T-cell-replete bone marrow grafts
    Ephraim J Fuchs
    Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21287, USA
    Curr Opin Hematol 19:440-7. 2012
    ....
  4. pmc Haploidentical transplantation for hematologic malignancies: where do we stand?
    Ephraim J Fuchs
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA
    Hematology Am Soc Hematol Educ Program 2012:230-6. 2012
    ..Prospective comparisons between haploidentical SCT and unrelated donor SCT should be performed to identify the most efficacious approach to alternative donor transplantation...
  5. ncbi request reprint Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation
    Leo Luznik
    Divisions of Hematologic Malignancies and Immunology Hematopoiesis, Johns Hopkins Oncology Center, Baltimore, MD 21231, USA
    Cancer Control 9:123-37. 2002
    ..Patients with hematologic malignancies in relapse after allogeneic bone marrow transplantation can be treated by infusing leukocytes from the original stem cell donor...
  6. pmc HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide
    Leo Luznik
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Biol Blood Marrow Transplant 14:641-50. 2008
    ..02). Nonmyeloablative HLA-haploidentical BMT with posttransplantation Cy is associated with acceptable rates of fatal graft failure and severe aGVHD or cGVHD...
  7. pmc Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes
    Erica D Warlick
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, United States
    Leuk Res 32:1439-47. 2008
    ..These results suggest that it is possible to maintain treatment intensity while minimizing toxicity in older, high-risk MDS patients...
  8. pmc High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation
    Leo Luznik
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 288 Bunting Blaustein Cancer Research Building, Baltimore, MD 21231, USA
    Immunol Res 47:65-77. 2010
    ..By reducing the morbidity and mortality of alloHSCT, post-transplantation Cy may expand the applications of this therapy to the treatment of autoimmune diseases and non-malignant hematologic disorders such as sickle cell disease...
  9. pmc The allogeneic effect revisited: exogenous help for endogenous, tumor-specific T cells
    Heather J Symons
    Division of Cancer Immunology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Biol Blood Marrow Transplant 14:499-509. 2008
    ..These events provide the cellular mechanism of the "allogeneic effect" in antitumor immunity. Cy + CD8(-) DLI may be an effective and minimally toxic strategy for awakening the host immune response to advanced cancers...
  10. pmc High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomas
    Douglas E Gladstone
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21287, USA
    Leuk Lymphoma 52:2076-81. 2011
    ..The 5-year EFS and OS for patients with MCL were 39% and 62%, respectively. This low-toxicity therapeutic approach obviates the need for stem cell products and establishes a platform for future therapies...
  11. pmc Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation
    Heather J Symons
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, 1650 Orleans Street, Baltimore, MD 21231, USA
    Biol Blood Marrow Transplant 16:533-42. 2010
    ..These findings suggest that selection of donors based upon inhibitory KIR gene or haplotype incompatibility may be warranted...
  12. ncbi request reprint Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells
    Carol Ann Huff
    Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Baltimore, MD, USA
    Biol Blood Marrow Transplant 9:312-9. 2003
    ..Unlike chronic myelogenous leukemia, the antimyeloma effect of allogeneic T cells rarely occurs in the absence of clinically significant GVHD...
  13. pmc Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome
    Yvette L Kasamon
    Johns Hopkins University, 1650 Orleans Street, Baltimore, MD 21231, USA
    Biol Blood Marrow Transplant 16:482-9. 2010
    ..55, P = .03 for 3-4 vs fewer allele mismatches). Thus, greater HLA disparity does not appear to worsen overall outcome after NMA haploidentical BMT with high-dose posttransplantation cyclophosphamide...
  14. pmc HLA-haploidentical stem cell transplantation for hematologic malignancies
    Ephraim J Fuchs
    Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Biol Blood Marrow Transplant 16:S57-63. 2010
    ..The availability of multiple potential HLA-haploidentical related donors for most patients opens the possibility of optimizing transplantation outcome through intelligent donor selection...
  15. pmc High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease
    Leo Luznik
    Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Blood 115:3224-30. 2010
    ..These results suggest that high-dose posttransplantation cyclophosphamide is an effective single-agent prophylaxis of acute and chronic GVHD after BuCy conditioning and HLA-matched BMT (clinicaltrials.gov no. NCT00134017)...
  16. pmc High-dose cyclophosphamide for graft-versus-host disease prevention
    Leo Luznik
    Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Curr Opin Hematol 17:493-9. 2010
    ..This strategy has recently been adapted to human transplantation...
  17. ncbi request reprint Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia
    Robert Iannone
    Department of Pediatrics, Johns Hopkins Hospital and Oncology Center, Baltimore, Maryland, USA
    Biol Blood Marrow Transplant 9:519-28. 2003
    ....
  18. pmc Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma
    Javier BolaƱos-Meade
    George W Santos Bone Marrow Transplant Service, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Biol Blood Marrow Transplant 13:1185-91. 2007
    ..The administration of oral cyclosporine followed by interleukin-2 and gamma-interferon is generally not well tolerated, and does not appear to be an effective method to induce autologous GVHD in patients receiving autologous PBSC grafts...
  19. ncbi request reprint Nonmyeloablative alternative donor transplants
    Leo Luznik
    Divisions of Hematologic Malignancies and Immunology Hematopoiesis, Johns Hopkins Oncology Center, Baltimore, Maryland, USA
    Curr Opin Oncol 15:121-6. 2003
    ..Early clinical results suggest that the use of alternative donors is feasible, therefore potentially allowing full extension of the benefits of allografting to the group of patients in highest need...
  20. ncbi request reprint Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions
    Carol Ann Huff
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, Baltimore, MD 21231, USA
    Biol Blood Marrow Transplant 12:414-21. 2006
    ..However, with the exception of CML, most patients die of their underlying disease because of insufficient antitumor activity even with active GVHD...
  21. ncbi request reprint Autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide purging for acute myeloid leukaemia beyond first remission: a 10-year experience
    B Douglas Smith
    Johns Hopkins Oncology Center, Bunting Blaustein Cancer Research Building, Rm 246, 1650 Orleans Street, Baltimore, MD 21231, USA
    Br J Haematol 117:907-13. 2002
    ..4HC-purged autologous BMT produced results similar to allogeneic BMT for AML patients beyond first remission...
  22. pmc High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up
    Robert A Brodsky
    Division of Hematology, Department of Medicine, Johns Hopkins University School ofMedicine, 720 Rutland Ave, Ross Bldg, Rm 1025, Baltimore, MD 21205, USA
    Blood 115:2136-41. 2010
    ....
  23. pmc Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution
    Amy E Dezern
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Biol Blood Marrow Transplant 17:1404-9. 2011
    ..Our single-institution study of consecutively treated AML patients supports the hypothesis that allogeneic transplant in early CR1 improves the long-term outcomes for FLT3/ITD AML...
  24. doi request reprint Alternative transplant donor sources: is there any consensus?
    Ephraim Fuchs
    Blood and Marrow Transplantation Programs, Johns Hopkins University, Baltimore, Maryland, USA
    Curr Opin Oncol 25:173-9. 2013
    ..To review the data supporting the use of alternative donors for hematopoietic cell transplantation of patients with high-risk or advanced hematological malignancies...
  25. ncbi request reprint Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras
    Leo Luznik
    Divisions of Hematopoiesis Immunology and Hematologic Malignancies, Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Blood 101:1645-52. 2003
    ....
  26. ncbi request reprint Host-derived Langerhans cells persist after MHC-matched allografting independent of donor T cells and critically influence the alloresponses mediated by donor lymphocyte infusions
    Nadira Durakovic
    Divisions of Hematologic Malignancies and Cancer Immunology and Hematopoiesis, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Baltimore, MD 21231, USA
    J Immunol 177:4414-25. 2006
    ....
  27. pmc Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse
    Nadira Durakovic
    Divisions of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Blood 109:4564-74. 2007
    ....
  28. doi request reprint Hematopoietic stem cell transplantation for chronic lymphocytic leukemia
    Douglas E Gladstone
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA
    Curr Opin Oncol 24:176-81. 2012
    ..Now in the era of improved conventional treatment and better prognostication of long-term outcome, a review of autologous and allogeneic HSCT in CLL treatment is warranted...
  29. ncbi request reprint Immunotherapy of established tumors using bone marrow transplantation with antigen gene--modified hematopoietic stem cells
    Yan Cui
    Immunology and Hematopoiesis Division, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Nat Med 9:952-8. 2003
    ..This tripartite strategy provided potent antigen-specific immunotherapy for an aggressive established tumor...
  30. ncbi request reprint Association of Foxp3 regulatory gene expression with graft-versus-host disease
    Yuji Miura
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Blood 104:2187-93. 2004
    ..The decrease in regulatory mechanisms after transplantation appears to provide an environment permissive to the development of GVHD...
  31. pmc Cyclophosphamide unmasks an antimetastatic effect of local tumor cryoablation
    Moshe Yair Levy
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    J Pharmacol Exp Ther 330:596-601. 2009
    ..The combination of tumor cryoablation and Cy induces potent, systemic antitumor immunity in animals with established metastatic disease...
  32. ncbi request reprint Resistance of cancers to immunologic cytotoxicity and adoptive immunotherapy via X-linked inhibitor of apoptosis protein expression and coexisting defects in mitochondrial death signaling
    Rajani Ravi
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, 1650 Orleans Street, Baltimore, MD 21231, USA
    Cancer Res 66:1730-9. 2006
    ....
  33. ncbi request reprint Bone marrow transplantation for sickle cell anemia: progress and prospects
    Robert Iannone
    The Children s Hospital of Philadelphia, Division of Oncology, Philadelphia, Pennsylvania 19104, USA
    Pediatr Blood Cancer 44:436-40. 2005

Research Grants6

  1. Restoring T Cell Responses to Therapeutic Tumor Vaccines
    Ephraim Fuchs; Fiscal Year: 2009
    ....
  2. Restoring T Cell Responses to Therapeutic Tumor Vaccines
    Ephraim Fuchs; Fiscal Year: 2005
    ....
  3. Restoring T Cell Responses to Therapeutic Tumor Vaccines
    Ephraim Fuchs; Fiscal Year: 2006
    ....
  4. Restoring T Cell Responses to Therapeutic Tumor Vaccines
    Ephraim Fuchs; Fiscal Year: 2007
    ....
  5. Allogeneic lymphocyte infusions to treat myeloid cancers
    Ephraim Fuchs; Fiscal Year: 2007
    ..Unfortunately, some of the cells, called CD8+ T cells, can destroy normal tissues as well. We wish to test whether removal of these CD8+ T cells enhances the safety of WBC transfusions for patients with blood cancers. ..